Endocrine Abstracts

Thyrotropin-secreting pituitary tumors are <1% of pituitary adenomas. Clinical manifestations are similar to other forms of hyperthyroidism. Most of them are diagnosed as macroadenoma (microadenomas <10%).Case 1: A 48 years old woman with menopause presented 6 years ago, consulting in 2009 for weight loss and palpitations. She had elastic goiter and distal tremor. Blood test: TSH 8.66 μUI/ml (0.2–4.2), FT4 4.7 ng/dl (0.7&#150...

Blackground: Parathyroid carcinoma is a malignant neoplasm affecting 0.5 to 5.0% of all patients suffering from primary hyperparathyroidism. This cancer continues to cause challenges for diagnosis and treatment because of its rarity, overlapping features with benign parathyroid disease.Case report: 50 years-old-woman, without relevant previous history. She begins to present asthenia, weakness of lower limbs, arthralgias, cramps and appearance of a painfu...

Objective: To evaluate the efficacy of liraglutide, a new glucagon-like peptide 1 analogue, on glycaemic control, body weight, blood pressure and lipid profile in obese patients with type 2 diabetes mellitus (T2DM).Material and methods: Patients attending a tertiary Endocrinology Unit who were prescribed liraglutide (January 2013–December 2013) and assessed both at baseline and first post-initiation visit were included in the analysis. The primary e...

Objective: The aim of this study is to evaluate the effectiveness of once-weekly exenatide on metabolic control, weight, blood pressure, and lipid profile in obese patients with type 2 diabetes (T2DM), and to assess possible predictive factors of response.Material and methods: Retrospective observational study, conducted with adult obese (BMI ≥30 kg/m2) T2DM subjects that had been initiated once-weekly exenatide following routine clinica...

Introduction: New treatments of diabetes improve global metabolic status beyond glycemic control and achieve weight reduction in many patients.Case reports: We described four case reports to show GLP-1 agonists and dapaglifozin effects on metabolism and weight in patients with type 2 diabetes and obesity.Case 1 (Liraglutide): A 48-year-old man, hypertension, type 2 diabetes and extreme obesity. Baseline visit: treatment enalapril 2...